© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Padcev

Male reproductive system

Padcev Boosts Survival for People With Advanced Bladder Cancer

The antibody-drug conjugate extended survival by four months compared with chemotherapy.

Padcev Improves Overall Survival in People With Bladder Cancer

The 30% improvement in survival has brought a Phase III trial to an early halt.

Special Delivery: Antibody-Drug Conjugates

Last year, the FDA approved three new antibody-drug conjugates for treating cancer.

Padcev Combo Continues to Show Promise for Advanced Bladder Cancer

Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.

Top 10 Cancer Treatment Highlights of 2019

Padcev

FDA Approves Padcev for Advanced Bladder Cancer

Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.

New Combo Shows Promise as Treatment for Advanced Bladder Cancer

Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.

New Targeted Antibody Treatment for Bladder Cancer Shows Promise

More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
Advertisement

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.